ViewPoint Therapeutics
953 Indiana Street
San Francisco
California
United States
2 articles with ViewPoint Therapeutics
-
A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval.
-
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
9/28/2022
Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.